Aspira Pathlab & Diagnostics Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.

Regulatory Compliance Submission

The healthcare diagnostics company filed the compliance certificate on January 07, 2026, as mandated under Regulation 74(5) of the SEBI regulations. The certificate was issued by MUFG Intime India Private Limited, formerly known as Link InTime India Private Limited, which serves as the company's Registrar & Share Transfer Agent.

Certificate Confirmation Details

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories. The registrar verified that:

• Securities received for dematerialisation were confirmed or rejected within prescribed timelines
• Security certificates were mutilated and cancelled after due verification by depository participants
• Depository names were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed

Company Information

Aspira Pathlab & Diagnostics Limited operates as India's first fully integrated laboratory, with its registered office located in Ghatkopar (West), Mumbai. The company is incorporated under CIN L85100MH1973PLC289209 and trades on BSE with scrip code 540788 under the security ID ASPIRA.

The compliance certificate was signed by Krupali Shah, Company Secretary & Compliance Officer, and Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, ensuring proper authorization and documentation of the regulatory submission.

Aspira Pathlab & Diagnostics Limited has announced the demise of its Independent Director Dr. Alaka Keshav Deshpande, who passed away on December 30, 2025, at the age of 79. The company informed BSE Limited about this development under Regulation 30 of SEBI (LODR) Regulations, 2015.

Board Leadership Changes

Dr. Deshpande's death has resulted in her cessation from the office of Independent Director effective from December 30, 2025. The company described her sudden and unexpected demise as an irreparable loss to the organization.

The following table outlines the key details of the directorship change:

Committee Memberships Affected

Dr. Deshpande's demise has also resulted in the cessation of her membership in multiple board committees. She served as a member of three critical committees that oversee various aspects of corporate governance.

Her committee positions included:

• Audit Committee - Member
• Nomination & Remuneration Committee - Member
• Stakeholder Relationship Committee - Member

Regulatory Compliance

The company has fulfilled its disclosure obligations by informing the stock exchange as required under SEBI regulations. According to the filing, Dr. Deshpande did not hold directorships in any other listed entities at the time of her demise.

Company Secretary & Compliance Officer Krupali Shah signed the regulatory filing submitted to BSE Limited. The company's scrip code is 540788 and trades under the security ID ASPIRA.

Corporate Response

All directors and employees of Aspira Pathlab & Diagnostics Limited have conveyed deep condolences to Dr. Deshpande's family during this difficult time. The company acknowledged her contributions and the significant impact her loss will have on the organization's leadership structure.